253 related articles for article (PubMed ID: 26265276)
1. CD20+inflammatory T-cells are present in blood and brain of multiple sclerosis patients and can be selectively targeted for apoptotic elimination.
Holley JE; Bremer E; Kendall AC; de Bruyn M; Helfrich W; Tarr JM; Newcombe J; Gutowski NJ; Eggleton P
Mult Scler Relat Disord; 2014 Sep; 3(5):650-8. PubMed ID: 26265276
[TBL] [Abstract][Full Text] [Related]
2. Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists.
Bremer E; ten Cate B; Samplonius DF; Mueller N; Wajant H; Stel AJ; Chamuleau M; van de Loosdrecht AA; Stieglmaier J; Fey GH; Helfrich W
Cancer Res; 2008 Jan; 68(2):597-604. PubMed ID: 18199557
[TBL] [Abstract][Full Text] [Related]
3. Selective elimination of pathogenic synovial fluid T-cells from rheumatoid arthritis and juvenile idiopathic arthritis by targeted activation of Fas-apoptotic signaling.
Bremer E; Abdulahad WH; de Bruyn M; Samplonius DF; Kallenberg CG; Armbrust W; Brouwers E; Wajant H; Helfrich W
Immunol Lett; 2011 Aug; 138(2):161-8. PubMed ID: 21514322
[TBL] [Abstract][Full Text] [Related]
4. Depletion of functionally active CD20+ T cells by rituximab treatment.
Wilk E; Witte T; Marquardt N; Horvath T; Kalippke K; Scholz K; Wilke N; Schmidt RE; Jacobs R
Arthritis Rheum; 2009 Dec; 60(12):3563-71. PubMed ID: 19950291
[TBL] [Abstract][Full Text] [Related]
5. Proinflammatory CD20+ T cells in the pathogenesis of multiple sclerosis.
von Essen MR; Ammitzbøll C; Hansen RH; Petersen ERS; McWilliam O; Marquart HV; Damm P; Sellebjerg F
Brain; 2019 Jan; 142(1):120-132. PubMed ID: 30561509
[TBL] [Abstract][Full Text] [Related]
6. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro.
Gall JM; Davol PA; Grabert RC; Deaver M; Lum LG
Exp Hematol; 2005 Apr; 33(4):452-9. PubMed ID: 15781336
[TBL] [Abstract][Full Text] [Related]
7. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?
Bar-Or A; Fawaz L; Fan B; Darlington PJ; Rieger A; Ghorayeb C; Calabresi PA; Waubant E; Hauser SL; Zhang J; Smith CH
Ann Neurol; 2010 Apr; 67(4):452-61. PubMed ID: 20437580
[TBL] [Abstract][Full Text] [Related]
8. Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients.
Palanichamy A; Jahn S; Nickles D; Derstine M; Abounasr A; Hauser SL; Baranzini SE; Leppert D; von Büdingen HC
J Immunol; 2014 Jul; 193(2):580-586. PubMed ID: 24928997
[TBL] [Abstract][Full Text] [Related]
9. Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis.
Kebir H; Ifergan I; Alvarez JI; Bernard M; Poirier J; Arbour N; Duquette P; Prat A
Ann Neurol; 2009 Sep; 66(3):390-402. PubMed ID: 19810097
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic.
de Sèze J; Maillart E; Gueguen A; Laplaud DA; Michel L; Thouvenot E; Zephir H; Zimmer L; Biotti D; Liblau R
Front Immunol; 2023; 14():1004795. PubMed ID: 37033984
[TBL] [Abstract][Full Text] [Related]
11. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis.
Mehling M; Lindberg R; Raulf F; Kuhle J; Hess C; Kappos L; Brinkmann V
Neurology; 2010 Aug; 75(5):403-10. PubMed ID: 20592255
[TBL] [Abstract][Full Text] [Related]
12. Frequency of Th17 CD20+ cells in the peripheral blood of rheumatoid arthritis patients is higher compared to healthy subjects.
Eggleton P; Bremer E; Tarr JM; de Bruyn M; Helfrich W; Kendall A; Haigh RC; Viner NJ; Winyard PG
Arthritis Res Ther; 2011; 13(6):R208. PubMed ID: 22171710
[TBL] [Abstract][Full Text] [Related]
13. CD16+ gammadelta T cells mediate antibody dependent cellular cytotoxicity: potential mechanism in the pathogenesis of multiple sclerosis.
Chen Z; Freedman MS
Clin Immunol; 2008 Aug; 128(2):219-27. PubMed ID: 18501678
[TBL] [Abstract][Full Text] [Related]
14. High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes.
Leussink VI; Jung S; Merschdorf U; Toyka KV; Gold R
Arch Neurol; 2001 Jan; 58(1):91-7. PubMed ID: 11176941
[TBL] [Abstract][Full Text] [Related]
15. Specific central nervous system recruitment of HLA-G(+) regulatory T cells in multiple sclerosis.
Huang YH; Zozulya AL; Weidenfeller C; Metz I; Buck D; Toyka KV; Brück W; Wiendl H
Ann Neurol; 2009 Aug; 66(2):171-83. PubMed ID: 19705413
[TBL] [Abstract][Full Text] [Related]
16. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance.
Hoffmann TK; Dworacki G; Tsukihiro T; Meidenbauer N; Gooding W; Johnson JT; Whiteside TL
Clin Cancer Res; 2002 Aug; 8(8):2553-62. PubMed ID: 12171883
[TBL] [Abstract][Full Text] [Related]
17. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis.
Monson NL; Cravens PD; Frohman EM; Hawker K; Racke MK
Arch Neurol; 2005 Feb; 62(2):258-64. PubMed ID: 15710854
[TBL] [Abstract][Full Text] [Related]
18. IL-15 amplifies the pathogenic properties of CD4+CD28- T cells in multiple sclerosis.
Broux B; Mizee MR; Vanheusden M; van der Pol S; van Horssen J; Van Wijmeersch B; Somers V; de Vries HE; Stinissen P; Hellings N
J Immunol; 2015 Mar; 194(5):2099-109. PubMed ID: 25617471
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse.
Wang HH; Dai YQ; Qiu W; Lu ZQ; Peng FH; Wang YG; Bao J; Li Y; Hu XQ
J Clin Neurosci; 2011 Oct; 18(10):1313-7. PubMed ID: 21795048
[TBL] [Abstract][Full Text] [Related]
20. CX(3)CR1 drives cytotoxic CD4(+)CD28(-) T cells into the brain of multiple sclerosis patients.
Broux B; Pannemans K; Zhang X; Markovic-Plese S; Broekmans T; Eijnde BO; Van Wijmeersch B; Somers V; Geusens P; van der Pol S; van Horssen J; Stinissen P; Hellings N
J Autoimmun; 2012 Feb; 38(1):10-9. PubMed ID: 22123179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
